NASDAQ:RDUSRadius Health Stock Price, Forecast & News

Radius Health's stock was trading at $16.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RDUS stock has decreased by 17.4% and is now trading at $13.27. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Radius Health.

Radius Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Radius Health.

Radius Health Inc (NASDAQ:RDUS) posted its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.09. The biopharmaceutical company earned $47.92 million during the quarter, compared to analyst estimates of $46.77 million. View Radius Health's earnings history.

Radius Health issued an update on its FY 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $190-220 million, compared to the consensus revenue estimate of $225.56 million.

8 brokerages have issued 1-year price objectives for Radius Health's shares. Their forecasts range from $17.00 to $40.00. On average, they anticipate Radius Health's stock price to reach $25.57 in the next year. This suggests a possible upside of 92.7% from the stock's current price. View analysts' price targets for Radius Health.

Media stories about RDUS stock have trended negative on Friday, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Radius Health earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Radius Health.

Some companies that are related to Radius Health include Amarin (AMRN), Opko Health (OPK), Taro Pharmaceutical Industries (TARO), Apellis Pharmaceuticals (APLS), Pacira Biosciences (PCRX), Turning Point Therapeutics (TPTX), SAGE Therapeutics (SAGE), IGM Biosciences (IGMS), Uniqure (QURE), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA), Principia Biopharma (PRNB), Xencor (XNCR) and Prestige Consumer Healthcare (PBH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), EXACT Sciences (EXAS), Cara Therapeutics (CARA), Amarin (AMRN), Opko Health (OPK), Portola Pharmaceuticals (PTLA), Netflix (NFLX), ACADIA Pharmaceuticals (ACAD) and Micron Technology (MU).

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RDUS stock can currently be purchased for approximately $13.27.

Radius Health has a market capitalization of $615.58 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Radius Health employs 398 workers across the globe.

The official website for Radius Health is www.radiuspharm.com.

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]